Can GLP-1 Receptor Agonists Cause Palpitations?
GLP-1 receptor agonists (GLP-1 RAs) can cause palpitations, primarily through a modest increase in heart rate (typically 2-5 beats per minute), but they do not increase overall risk of clinically significant cardiac arrhythmias and are considered cardiovascularly safe. 1, 2
Mechanism of Heart Rate Increase
GLP-1 RAs consistently increase resting heart rate through multiple pathways:
- Direct chronotropic effect: Heart rate increases by approximately 2-4 beats per minute with liraglutide and similar agents 3, 2
- Autonomic modulation: The effect requires intact autonomic nervous system function and does not occur in isolated heart preparations, indicating it is not a direct cardiac effect 4
- Sympathetic activation: Systemic GLP-1 RA administration causes mild sympathetic activation, though paradoxically the drugs also enhance parasympathetic (vagal) tone 5, 4
This heart rate increase is a class effect that occurs across all GLP-1 RAs and is acknowledged in multiple guidelines 1, 3. Patients may perceive this as palpitations, particularly when initiating therapy or during dose escalation.
Arrhythmia Risk: The Evidence
The overall arrhythmia risk is reassuring:
Meta-analysis of 56 RCTs (79,720 participants) found GLP-1 RAs did not significantly increase risk of atrial fibrillation (RR 0.97), atrial flutter (RR 0.83), ventricular arrhythmias (RR 1.24), or sudden cardiac death (RR 0.89) compared to controls 6
Cardiovascular outcomes trials consistently showed neutral or beneficial effects on heart failure hospitalization 7, 8, with no safety signals for clinically significant arrhythmias
Antiarrhythmic properties: Preclinical evidence suggests GLP-1 RAs may actually reduce ventricular arrhythmia susceptibility by opposing β-adrenergic stimulation effects and enhancing vagal tone 5, 9
Important Nuances and Caveats
Drug-specific considerations:
- Dulaglutide showed a trend toward increased atrial fibrillation in subgroup analysis (RR 1.40) 6
- Albiglutide (no longer available) was associated with more atrial fibrillation/flutter cases (1.4% vs 0.6%) in meta-analysis 3
- Oral semaglutide showed an inverse trend for atrial fibrillation (RR 0.43) 6
Patient-specific factors:
- Higher baseline BMI may increase ventricular arrhythmia risk (RR 1.60) 6
- Elderly patients may be more susceptible to arrhythmogenic effects, particularly with acute administration 10
- The SCALE Diabetes trial reported more cardiac arrhythmias with liraglutide 3 mg (5 vs 2 events per 100 patient-years), mostly sinus tachycardia 3
Clinical Management Approach
When prescribing GLP-1 RAs:
Inform patients that mild heart rate increase and occasional palpitations are expected, particularly in the first 4 weeks 11
Monitor symptomatic patients: If palpitations are bothersome, consider beta-blockers for symptomatic relief 2
Titrate slowly: Start at the lowest dose and up-titrate gradually to minimize cardiovascular side effects 11
Do not withhold in cardiovascular disease: GLP-1 RAs with proven cardiovascular benefit (liraglutide, semaglutide, dulaglutide) are recommended for patients with diabetes and established cardiovascular disease 7, 11
Use caution but do not contraindicate in patients with pre-existing arrhythmias, as the overall safety profile is favorable 1, 8
Bottom Line
While GLP-1 RAs cause a predictable, modest increase in heart rate that patients may perceive as palpitations, they do not increase the risk of clinically significant arrhythmias. The cardiovascular benefits—including reduced major adverse cardiovascular events and mortality—far outweigh this minor side effect in appropriate patients 7, 11, 12. The sensation of palpitations should be acknowledged and monitored but should not preclude use of these agents in patients who would otherwise benefit from them.